Public Policy Letters, Statements, Legal Briefs, & Other Responses
-
ACMG Comments on FDA Plausible Mechanism Draft Guidance
-
Sign-on Letter to Evicore Regarding Interpretation of NCCN Guidelines
-
ACMG Response to RFI on Gene Therapies Access for Rare Diseases
-
Sign-on Letter Regarding the Novitas & FCSO Proposed LCD on Genetic Testing for Oncology
-
ACMG Comment to NCD on Germline Editing and Impact on People with Disabilities
-
Sign-on Letter Supporting the Reducing Hereditary Cancer Act
-
ACMG Response to USPSTF Proposed Research Plan for Lynch Syndrome
-
ACMG Letter to Michigan Medicaid on Coverage of Prenatal & Carrier Screening